Bringing LSPR Nanotechnology to POC and Mobile Diagnostics
LamdaGen’s L’AuRa digital platform enables diagnostic sensitivities and precise quantitation at levels far beyond the expected. The Company’s patented plasmonic technologies (LSPR nanotechnology) produces highly robust biosensors in the form of nanostructured metallic thin-films that exhibit remarkable optical detection capabilities.
The Company’s L’AuRa Point of Care (POC) diagnostic platform enables an important performance shift away from traditional central laboratory analog testing to a rapid decentralized digital one. The L’AuRa testing system delivers rapid quantitative results in small mobile formats at the point of clinical need.
Saliva-based Cortisol Assay: Read More ›
Troponin I (cTnI) Ap Note: Read More ›
L’AuRa Platform for Next-Generation Diagnostics: Read More ›